DESCRIPTION OF ENGENE SECURITIESenGene Holdings Inc. • January 29th, 2024 • Biological products, (no disgnostic substances)
The following description of the material terms of the enGene Holdings Inc.’s (“enGene”) share capital is not a complete summary of the rights and preferences of such securities and is qualified by reference to the Articles of enGene (“Articles”), as may be amended from time to time. You are encouraged to read the Articles and the Warrant Agreement, dated December 9, 2021, between Forbion European Acquisition Corporation (“FEAC”) and Continental Stock Transfer & Trust Company, and warrant agreement, as amended and assumed by enGene pursuant to the Warrant Assignment, Assumption and Amendment Agreement, dated as of October 30, 2023, which are incorporated by reference to the Annual Report on Form 10-K for the year ended October 31, 2023, for a complete description of the rights and preferences of our Common Shares and Warrants. This section also summarizes relevant provisions of the Business Corporations Act (British Columbia) (the “BCBCA”). The terms of the BCBCA are more detailed than
